J&J reorganizes QC functions
This article was originally published in The Tan Sheet
Executive Summary
A new company-wide framework will help "facilitate more effective coordination of Johnson & Johnson's quality, compliance and supply chain organizations," according to Corporate Communication VP Jeffrey Leebaw. The spokesman said in an e-mail that CEO William Weldon announced the plan internally the week of Aug. 15 and appointed Corporate VP Ajit Shetty to oversee the new framework. Chief quality officers also will be named for J&J's consumer, pharmaceutical and medical device businesses, Leebaw added. Recalls of OTCs made by J&J's McNeil Consumer Healthcare subsidiary have attracted FDA and congressional investigations and the firm has spent much of 2010 plotting remediation of its manufacturing shortcomings (1"The Tan Sheet" Aug. 9, 2010)
You may also be interested in...
CDER Enforcement Priorities Include Quality Control, Drug "Criminalization"
FDA's Center for Drug Evaluation and Research will crack down on manufacturers that attempt to "farm out responsibility," firms that fail to meet reporting requirements and the general "criminalization of our drug supply," said Deb Autor, director of the center's compliance office
J&J/McNeil Done With Post-Recall Personnel Changes - CEO Weldon
Johnson & Johnson has finished culling its ranks of employees responsible for quality control lapses that led to extensive OTC recalls, according to CEO William Weldon.
J&J Keeps Expectations Conservative For OTC Manufacturing Remediation
Johnson & Johnson expects the resumption of manufacturing the children's OTC drugs the firm's McNeil Consumer Healthcare business recalled this year may be as far off as April 2011